The protein product of Nm23 gene has recently been proposed to play an important role in tumour metastasis suppression Steeg et al., 1989) . The Nm23 protein has substantial homology with the protein encoded by a Drosophila abnormal wing discs (awd) developmental gene, and nucleoside diphosphate (NDP) kinase, which catalyses the phosphorylation of nucleoside diphosphate into nucleoside triphosphates (Biggs, et al., 1990; Kimura et al., 1990; Wallet et al., 1990) . The abundance of Nm23 expression was described to be inversely correlate with metastatic potential in several rodent metastasis model systems: murine k-1735 melanomas Leone et al., 1991) , N-nitrosomethylurea-induced rat mammary tumours , mouse mammary tumour virusinduced tumours and cotransfected with ras alone or ras plus adenovirus 2E1A rat embryo fibroblasts . The expression of human Nm23 gene was also found to be lower in human breast cancer with high metastatic potential than in that with low metastatic potential (Bevilacqua et al., 1989; Barnes et al., 1991; Hennessy et al., 1991; Hirayama et al., 1991) . Such a correlation was, however, not observed in some other human tumours such as colon cancer (Haut et al., 1991) , neuroblastoma (Hailat et al., 1991) , and some solid tumours (Lacombe et al., 1991 for 18S ribosomal RNA as previously described (Shi et al., 1991) . The Nm23-H1 cDNA probe was labelled with [a-32P]-dCTP to a specific activity of I09 c.p.m. Lg-' using Pharmacia's random primer labelling kit. Hybridisation was performed at 42°C for 18 h in 6 x SSPE, 10 mM EDTA, 5xDenhardt's solution, 0.5% SDS, 100l gml-' denatured salmon testis DNA and 50% formamide. The membranes were then washed twice in 2 x SSPE at 65'C and exposed to Kodak XAR-5 film at -70'C with intensifying screens.
Following autoradiography band intensities were quantitated by a Bio-Rad scanning laser densitometry and normal- ised by comparison with the 18S ribosomal band. Comparison between specimen groups was done using the unpaired Student's t-test.
PCR-SSCP analysis Five ,sg of total RNA was reverse transcribed into cDNA in 15 LI volume, using Pharmacia's first-strand cDNA synthesis kit. Four PCR primers were synthesised, two of which (primer 1 and 4) flanked the coding region of the Nm23-HI gene and the other two (primer 2 and 3) were from the middle of the coding region. Primers 1 and 2 (5'-CAGCCG-GAGTTCAAACCTAA-3', 5'-TTGGTCTCCCCGAGCATG-ACT-3'), and Primers 3 and 4 (5'-GGGCTGAATGTGGTG-AAGACG-3', 5'-GGATGTGAAAAGCAATGTGG-3') were used to generate by PCR two overlapping fragments, each about 350 bp. 0.5 tl of tumour cDNA was used for PCR in Single-strand conformation polymorphism analysis was done as described previously (Orita et al., 1989a,b) . Briefly, 1 tlI of each amplified product was diluted in 20 jlI loading buffer containing 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol, and heated at 95°C for 3 min. Two yI was loaded into 5% non-denaturing polyacrylamide gel with 10% glycerol and run at room temperature, 30 watts for 6 h. The gel was then exposed to Kodak XAR-5 film overnight at -70°C.
DNA sequencing analysis DNA sequencing was performed by the dideoxy chain termination method after cloning the PCR products into TA cloning vector (Invitrogen Co., CA, USA). 
Results
The abundance of Nm23 mRNA was examined in tissues from five multinodular goitres and 34 thyroid tumours. Nm23 was expressed in all the thyroid tissue specimens. The expression level was, however, variable in different stages of thyroid carcinoma. (Figures 1 & 2) . The tumour specimens were reviewed by an independent pathologist. There was no clear correlation of Nm23 expression with the proportion of stromal tissues present in the tumour samples. It is, therefore, unlikely that stromal tissues contributed significantly to the high intra-group variation of Nm23 expression. The wide variation of Nm23 gene expression in different stage thyroid tumours may have resulted from mutations or deletions in the coding region of the gene. To rule out such a possibility, we screened for Nm23-HI gene mutations in these thyroid tumour specimens by RT-PCR-SSCP technique. Primers 1 and 4 were used to specifically amplify Nm23-Hl coding sequence. No mutations were found although we did find p53 mutations in nine of these tumour specimens using the same cDNA mix and technique. Four cDNA samples generated by PCR were randomly chosen and the coding region was sequenced. Two of them were from anaplastic carcinoma specimens which had high level Nm23 expression, whereas the other two were from papillary carcinoma specimens which had reduced Nm23 expression. None of the specimens sequenced was found to have mutations.
Discussion
The data presented herein demonstrate that Nm23 was expressed in both benign and malignant thyroid lesions. By contrast to the findings reported in some tumours such as breast cancer (Bevilacqua et al., 1989; Barnes et al., 1991; Hennessy et al., 1991; Hirayama et al., 1991) and melanoma Leone et al., 1991) that high metastatic potential correlates with lower Nm23 expression, our results show that the expression of Nm23 is further increased in advanced stage of thyroid carcinomas. The mechanism for this increase and its effect on the tumour progression is not clear. It is likely that in certain tumours such as neuroblastoma (Hailat et al., 1991) , colon cancer (Haut et al., 1991) and thyroid tumour (this study), Nm23 expression reflects cell proliferation. This conclusion is supported by recent study showing Nm23-Hl expression is related to cell proliferation (Keim et al., 1992) and our unpublished observation that Nm23 was expressed at higher levels in the early stage as compared to the late stage of mouse embryogenesis.
It is known that Nm23 gene product has NDP kinase activity which provides intracellular pools of nucleoside triphosphates (excluding ATP) required for nucleic acid synthesis (Liotta & Steeg, 1990; Gilles et al., 1991) . In many systems, NDP kinases have been found associated with GTP binding proteins including elongation factor (Walton & Gill, 1975; Ohtsuki & Yokoyama, 1987) , microtubules (Nickerson & Wells, 1984) and p21 (Ohtsuki et al., 1986) or Gsa (Kimura & Shimada, 1988; Otero, 1990) (Stahl et al., 1991) . The Nm23-H1 probe we used does not efficiently distinguish between the two Nm23 mRNAs. Northern blot hybridisation of Nm23-H2-specific probe to breast tumours and cell lines shows that Nm23-H2 expression was also reduced in high metastatic potential tumour cells but to a less extent than Nm23-Hl (Stahl et al., 1991) , indicating that the two genes are regulated independently. It is thus possible that the observed Nm23 expression in thyroid tumours could be one of several distinct forms of Nm23 that are variably expressed in different cell types and that could play different roles.
Somatic allelic deletions of Nm23-H1 (including homozygous deletions in colon cancer) have been reported in human cancers such as breast, kidney, colon and lung (Cohn et al., 1991; Leone et al., 1991) . Cohn et al. (1991) demonstrated that 73% patients with Nm23-HI deletions in colon cancer had distant metastases as compared to 20% without Nm23-HI deletions, supporting its anti-metastatic role in colon cancers. Their studies seem to contradict the report by Haut et al., who found that Nm23 mRNA levels were higher in invasive colon cancers (Haut et al., 1991) . Further studies are required to prove that the increased Nm23 product is not mutant forms. In our study, we have shown that no mutations were detected in the coding region of Nm23-H1 by SSCP technique. However, we cannot completely exclude the possibility of mutation, especially in the regulatory region of Nm23-H1. Moreover, we do not yet know whether allelic deletions of Nm23-HI or mutations of Nm23-H2 exist in thyroid tumours.
In summary, Nm23 is expressed in both benign and malignant thyroid lesions. No correlation could be demonstrated between high level Nm23 expression and its anti-metastatic potential. Therefore, Nm23 mRNA level cannot be used as a marker of low metastatic potential in thyroid carcinomas. The high level Nm23 expression in advanced thyroid carcinoma suggests that it may be participated in cell proliferation. Tissue-specific factors may be involved in the dissociation of Nm23 expression from its anti-metastatic activity.
